| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF9 |
| Uniprot No | P41273 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 71-254aa |
| 氨基酸序列 | REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLPSPRSE |
| 预测分子量 | 48.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF9重组蛋白的3篇参考文献示例(注：文献为模拟示例，实际引用需查询真实数据库)：
1. **文献名称**：*Recombinant TNFSF9 promotes T cell-mediated antitumor immunity in solid tumors*
**作者**：Chen Y, et al.
**摘要**：研究证明，重组TNFSF9蛋白通过激活CD137信号通路，显著增强肿瘤微环境中T细胞的存活与功能，在临床前模型中有效抑制肿瘤进展。
2. **文献名称**：*Structural and functional analysis of the TNFSF9-CD137 signaling complex*
**作者**：Wang X, et al.
**摘要**：通过冷冻电镜技术解析了重组TNFSF9蛋白与其受体CD137的复合物结构，揭示了其特异性结合的分子机制，为靶向该通路的药物设计提供依据。
3. **文献名称**：*Recombinant TNFSF9 as a novel adjuvant for cancer vaccines*
**作者**：Kim H, et al.
**摘要**：研究发现，重组TNFSF9联合肿瘤抗原疫苗可显著增强抗原特异性T细胞应答，延长荷瘤小鼠生存期，提示其作为免疫佐剂的潜在价值。
建议通过PubMed或Web of Science以“TNFSF9 recombinant protein”或“CD137L”为关键词检索最新文献以获取真实数据。
**Background of TNFSF9 Recombinant Protein**
TNFSF9 (tumor necrosis factor superfamily member 9), also known as CD137L or 4-1BB ligand, is a type II transmembrane protein belonging to the TNF superfamily. It functions as a ligand for the co-stimulatory receptor 4-1BB (CD137), primarily expressed on activated T cells, natural killer (NK) cells, and dendritic cells. The TNFSF9-4-1BB interaction plays a critical role in enhancing T-cell proliferation, survival, and cytokine production, thereby modulating adaptive immune responses.
Recombinant TNFSF9 protein is engineered through genetic techniques, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and structural fidelity. The soluble form often includes the extracellular domain, which retains receptor-binding activity. This recombinant protein is widely used in research to study immune cell activation, signaling pathways, and therapeutic potential in cancer immunotherapy.
In preclinical studies, TNFSF9 has shown promise as an immune activator. Agonistic antibodies targeting 4-1BB (rather than TNFSF9 itself) are being explored in clinical trials to boost antitumor immunity. However, recombinant TNFSF9 serves as a tool to dissect ligand-receptor dynamics and optimize strategies for modulating immune checkpoints. Its dual role—promoting effector T-cell responses while potentially regulating immunosuppressive pathways—highlights its complexity in immune homeostasis.
Beyond oncology, TNFSF9 is implicated in autoimmune and inflammatory diseases, making its recombinant form valuable for investigating therapeutic balancing of immune activation and tolerance. Challenges remain in minimizing off-target effects, but ongoing research underscores its potential as a versatile tool in immunology and drug development.
×
